Introduction
============

Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin\'s lymphoma (NHL) that usually involves lymph nodes and extranodal organs, such as the bone marrow, spleen and gastrointestinal tract. MCL is characterized by a subset of CD5^−^, CD20^−^, CD79a^−^ and cyclin D1^+^ tumor cells ([@b1-mco-0-0-792]). Skin involvement is very rare in MCL; in these cases, cutaneous lesions may represent the first symptom of the disease ([@b2-mco-0-0-792]). In the present report, a rare case of MCL with cutaneous involvement as the first manifestation of the disease is presented, along with a detailed 4-year follow up, and the previously reported cases of MCL with cutaneous manifestations are reviewed.

Case report
===========

A 55-year-old Caucasian woman was referred to our clinic in July, 2008 for investigation of a large subcutaneous nodule (\~4 cm) in the right infraorbital region. The patient reported that the tumor had increased in size over the previous 12 months ([Fig. 1](#f1-mco-0-0-792){ref-type="fig"}). The patient also described experiencing other symptoms, including fever, night sweats and weight loss. A physical examination revealed no other pathological findings and hypothyroidism was noted as a pre-existing condition.

Initial blood tests revealed a moderate decrease in the white blood cell count (3.86/nl), with an inverted cellular type (neutrophils: 74.4%; and lymphocytes: 14.6%), mildly elevated lactate dehydrogenase (233 U/l) and β2-microglobulin (2.9 mg/l) levels, with a normal hemoglobin concentration (12.6 g/dl) and platelet count (182/nl). The hepatic and renal functions were normal.

Excision of the nodular lesion was performed. Histological examination revealed a deep subcutaneous infiltration by a nodular mass of medium-sized lymphoid cells with irregular nuclei. Immunohistochemical analysis revealed a population of lymphoblasts that were strongly positive for CD5, CD20, CD79a, cyclin D1, sex-determining region Y-box 11 (SOX11) and Ki67 ([Fig. 2](#f2-mco-0-0-792){ref-type="fig"}), but negative for CD10 and CD23.

Contrast-enhanced computed tomography (CT) of the neck and thorax revealed a 3.2×5.5×3.6-cm hyperdense enhancing mass in the epipharynx, involving the left side of the tonsillar region/bed. Several enlarged cervical and axillary lymph nodes were enhanced bilaterally. Enlarged lymph nodes were also identified in the lesser curvature of the stomach, in the paraaortic and coeliac regions, and in the area between the inferior vena cava and the head of the pancreas ([Fig. 3](#f3-mco-0-0-792){ref-type="fig"}). Magnetic resonance imaging of the head revealed a 4.0×4.1×3.0-cm homogeneously-enhanced epipharyngeal mass growing through the choanae into the nasal cavity, with enlarged parapharyngeal lymph nodes bilaterally. There were no cerebral pathological findings. A bone marrow biopsy revealed diffuse infiltration by neoplastic lymphoma cells.

Based on the clinicopathological and immunohistochemical findings, the diagnosis of a cutaneous variant of MCL at stage IVEB was established. Furthermore, chronic hepatitis B of unknown origin was newly diagnosed. Antiviral therapy with entecavir was initiated. The patient received six cycles of adjuvant chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), administered once a day for 2 weeks, along with three cycles of intrathecal methotrexate as central nervous system (CNS) prophylaxis, with no associated side effects. After the initial chemotherapy treatments, stem cells were collected from the patient\'s bone marrow, in case of the need for relapse therapy with a peripheral blood stem cell transplant (PBSC).

After 10 weeks, the patient was restaged and found to have a complete remission (CR); she remained in CR until November, 2009, when she presented with a discrete axillary, inguinal and mesenteric nodal recurrence and bone marrow infiltration. The patient was treated with two cycles of rituximab, cisplatin, cytosine arabinoside and dexamethasone (R-DHAP) and one cycle of intrathecal methotrexate as CNS prophylaxis. Restaging by CT and bone marrow biopsy confirmed partial remission. Subsequently, the patient was consolidated with PBSC using etoposide, cytosine arabinoside and melphalane (BEAM conditioning regimen), which was associated with moderate to severe toxicity in the form of fatigue, neutropenic fever and *Clostridium difficile*-positive diarrhea. Following induction of an intensive antibiotic and infusion treatment regimen, the patient\'s symptoms and signs of infection regressed. At present, 2 years after PBSC and 4 years after the appearance of the skin lesion, the patient is well, with no evidence of relapse.

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Discussion
==========

MCL is a B-cell lymphoma that affects older patients, with a median age of incidence at 68 years. MCL represents \~6% of all NHL subtypes ([@b3-mco-0-0-792]) with a male-to-female incidence ratio of 3:1 ([@b4-mco-0-0-792],[@b5-mco-0-0-792]). The prevalence is estimated to be \~2--3 cases per 100,000 patients per year ([@b6-mco-0-0-792]). The overall median survival (OS) of MCL is \~3--5 years. Adjuvant chemotherapy with the R-CHOP regimen in patients with untreated MCL achieved an overall response rate of 96% ([@b7-mco-0-0-792],[@b8-mco-0-0-792]).

MCL occurs primarily in lymph nodes and extranodal organs, including the bone marrow, spleen and gastrointestinal tract. Skin involvement occurs in 2% of MCL cases and is associated with progressive disease ([@b4-mco-0-0-792],[@b9-mco-0-0-792]). Immunophenotypically, MCL consist of CD5^−^, CD19^−^, CD20^−^, CD22^−^, CD45^−^ and CD79a^+^ tumor cells that are usually negative for CD10, CD23 and BCL-6. The majority of MCLs are characterized by overexpression of cyclin D1, as a result of the t(11;14) (q13;q32)/CCND1-IGH translocation ([@b1-mco-0-0-792]).

SOX11 is a transcription factor that is involved in embryogenic development. Recent studies have demonstrated overexpression of SOX11 in MCL ([@b10-mco-0-0-792]), but its prognostic significance remains controversial. Nygren *et al* found that the OS of SOX11-negative cases was lower compared with that of SOX11-positive cases (median OS: 1.5 vs. 3.2 years, respectively; P=0.014) ([@b11-mco-0-0-792]). Conversely, Fernandez *et al* found that patients with SOX11-negative tumors developed a predominantly extranodal type of MCL and were characterized by longer survival compared with SOX11-positive cases (5-year OS rate, 78 vs. 36%, respectively; P=0.001) ([@b12-mco-0-0-792]).

Skin manifestations of MCL are rare. Thus far, detailed reports in the English literature have described only 22 patients with MCL exhibiting skin lesions. The median age at the time of diagnosis is 63.6 years (range, 22--89 years). The most common cutaneous lesion has been described as a nodule (occurring in 56.5% of all patients), with a male-to-female ratio of 17:6. The majority of the patients (73.9%) with this lesion also present with extracutaneous involvement, such as of the bone marrow, lymph nodes and spleen. Of the 22 MCL patients with cutaneous manifestations identified, 12 succumbed to the disease ([@b2-mco-0-0-792],[@b13-mco-0-0-792]--[@b23-mco-0-0-792]). In those cases, the mean survival time from the diagnosis of cutaneous manifestations to death was 11.2 months (range, 5 days-36 months). The published cases are summarized in [Table I](#tI-mco-0-0-792){ref-type="table"}.

We herein described a rare case of MCL with involvement of the skin in the right infraorbital region, with a detailed 4-year follow-up and review of the available literature. The patient\'s skin biopsy revealed that the neoplastic tumor cells exhibited the characteristic cytology of MCL and were positive for CD5, CD20, CD79a, cyclin D1 and SOX11. To the best of our knowledge, this is the first report of a case of MCL with SOX11-positive tumor cells in a skin lesion. Our patient remains alive and well, with no evidence of disease relapse. This study also highlights the need for further investigation, in order to elucidate the role of SOX11 in the pathogenesis and prognosis of MCL with cutaneous manifestations.

The authors wish to acknowledge the valuable contribution of Dr Thomas Koculak for the high-quality images.
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![Subcutaneous nodule in the right infraorbital region (arrows).](mco-04-05-0728-g00){#f1-mco-0-0-792}

![Histopathological findings of the subcutaneous nodule in the right infraorbital region. (A and B) Massive infiltration by medium-sized neoplastic lymphoid cells with irregular nuclei (haematoxylin and eosin staining; magnification, ×40 and ×200, respectively). Immunohistochemical staining revealed that the atypical lymphocytes were strongly positive for (C) CD20 (magnification, ×200), (D) cyclin D1 (magnification, ×200) and (E) sex-determining region Y-box 11 (magnification, ×400).](mco-04-05-0728-g01){#f2-mco-0-0-792}

![Computed tomography scans of (A) the abdomen, showing enlarged lymph nodes in the area of the pancreatic head and (B) the cervical region, showing a space-occupying lesion in the nasopharynx and displacement of the peripheral structures, minor perfusion centrally and missing inner linear structures (red circles).](mco-04-05-0728-g02){#f3-mco-0-0-792}

###### 

Reported cases of mantle cell lymphoma with cutaneous manifestations (modified and completed from Canpolat *et al*).

  First Author (Refs.)             Gender/age (yrs)   Skin lesion/site                                               Extracutaneous manifestations    IHC                                                     Follow-up
  -------------------------------- ------------------ -------------------------------------------------------------- -------------------------------- ------------------------------------------------------- -----------------------------
  Bertero ([@b2-mco-0-0-792])      M/51               Subcutaneous nodule/breast                                     LN, liver, spleen                CD5, CD19, CD21, CD22, CD23, CD24, CD74                 A (17 yrs after onset)
                                   F/78               Nodules/breast, back                                           None                             CD5, CD19, CD21, CD22, CD24, CD38, CD74                 D (3 yrs after diagnosis)
                                   M/43               Infiltrated plaques/back, face, arm                            LN, liver, spleen                CD5, CD19, CD20, CD21, CD23, CD24, CD25, CD45RA, CD74   A
                                   M/22               Nodules/breast                                                 None                             CD5, CD19, CD20, CD21, CD23, CD24, CD25, CD45RA, CD74   A (5 yrs after diagnosis)
  Geerts ([@b13-mco-0-0-792])      F/65               Nodules, forehead                                              LN, BM                           CD19, CD20, CD22                                        D (11 mo after diagnosis)
                                   F/77               Tumoral plaques/back, breast, arm                              Bronchus wall                    CD5, CD22                                               D (1.5 yrs after diagnosis)
  Martí ([@b14-mco-0-0-792])       F/61               Tumoral plaque/abdomen                                         LN, BM, tonsils                  CD5, CD19, CD20, CD45RA, cyclin D1, CD74                D (15 mo after diagnosis)
  Moody ([@b15-mco-0-0-792])       M/47               Nodules/ear                                                    LN, BM                           CD5, CD19, CD20, cyclin D1                              A (3 yrs after onset)
  Sen ([@b16-mco-0-0-792])         M/85               Macular rash/leg                                               LN, BM, buccal mucosa            CD5, CD20, cyclin D1                                    D (20 mo after diagnosis)
                                   M/76               Nodule/thigh                                                   None                             CD5, CD20, cyclin D1                                    A (30 mo after diagnosis)
                                   M/56               Nodules/chest                                                  BM, GI                           CD20, cyclin D1                                         A (21 mo after diagnosis)
                                   M/57               Maculopapular rash/legs                                        LN, BM, PB                       CD5, CD20, cyclin D1                                    D (9 mo after diagnosis)
                                   M/61               Plaques/flank, back, thigh                                     LN, BM, PB, leptomeninges        CD5, CD20, cyclin D1                                    D (4 mo after onset)
  Dubus ([@b17-mco-0-0-792])       M/56               Papules/breast, back                                           LN, BM, PB                       CD5, CD20, CD43                                         D (1 yr after onset)
                                   M/89               Infiltrated papules/breast, back, abdomen                      LN, BM, PB                       CD5, CD20, CD43                                         D (5 days after onset)
                                   M/72               Subcutaneous nodules/arm, axillary region                      LN, BM                           CD20, CD43, cyclin D1                                   A (1 yr after onset)
  Motegi ([@b18-mco-0-0-792])      M/62               Nodules, ulceras/back, upper extermities, chest, penis shaft   LN, tonsils, spleen, GI tract    CD5, CD20, CD43, cyclin D1                              A (4 mo after onset)
  Estrozi ([@b19-mco-0-0-792])     M/72               Nodule/face                                                    None                             CD5, CD20, CD45, cyclin D1                              A (6 mo after diagnosis)
  Ishibashi ([@b20-mco-0-0-792])   M/68               Nodules/thigh, arm                                             LN, BM, PB                       CD20, cyclin D1                                         D (3 mo after diagnosis)
  Canpolat ([@b21-mco-0-0-792])    F/49               Papules/face, shoulders, back, chest                           LN, BM, spleen                   CD5, CD20, CD43, CD79a, cyclin D1                       D (4 mo after onset)
  Zattra ([@b22-mco-0-0-792])      M/77               Nodules, plaques/entire body                                   None                             CD5, CD20, CD22, CD79a, cyclin D1                       A (28 mo after diagnosis)
  Lynch ([@b23-mco-0-0-792])       M/83               Nodules/thigh                                                  Could not be entirely excluded   CD5, CD20, CD79a, cyclin D1                             D (2 mo after diagnosis)
  Our case                         F/55               Subcutaneous nodule/face                                       LN, BM, tonsils                  CD5, CD20, CD79a, cyclin D1, SOX11                      A (4 yrs after diagnosis)

LN, lymph node; BM, bone marrow; PB, peripheral blood; IHC, immunohistochemistry; GI, gastrointestinal; SOX11, sex-determining region Y-box 11; A, alive; D, deceased.
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